Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
ConclusionsThis real-world study corroborates the RR at month 12 previously shown in interventional studies on TCZ-SC. Our data suggest there are no differences according to patient’s profile (age, BMI), methotrexate doses, and TCZ-SC use.Trial RegistrationNCT02608112.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Actemra | Arthritis | Methotrexate | Rheumatoid Arthritis | Rheumatology | Statistics | Study | Women